Maykel Cruz-Monteagudo

List of Publications by Year in Descending Order

 $\textbf{Source:} \ https://exaly.com/author-pdf/9116709/maykel-cruz-monteagudo-publications-by-year.pdf$

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39 785 16 27 g-index

42 858 4 3.69 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
39	CompScore: Boosting Structure-Based Virtual Screening Performance by Incorporating Docking Scoring Function Components into Consensus Scoring. <i>Journal of Chemical Information and Modeling</i> , 2019 , 59, 3655-3666	6.1	14
38	Ensemble-Based Modeling of Chemical Compounds with Antimalarial Activity. <i>Current Topics in Medicinal Chemistry</i> , 2019 , 19, 957-969	3	6
37	A desirability-based multi objective approach for the virtual screening discovery of broad-spectrum anti-gastric cancer agents. <i>PLoS ONE</i> , 2018 , 13, e0192176	3.7	11
36	Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug discovery. <i>Drug Discovery Today</i> , 2017 , 22, 994-1007	8.8	25
35	From flamingo dance to (desirable) drug discovery: a nature-inspired approach. <i>Drug Discovery Today</i> , 2017 , 22, 1489-1502	8.8	17
34	Consensus strategy in genes prioritization and combined bioinformatics analysis for preeclampsia pathogenesis. <i>BMC Medical Genomics</i> , 2017 , 10, 50	3.7	14
33	Fusing Docking Scoring Functions Improves the Virtual Screening Performance for Discovering Parkinson's Disease Dual Target Ligands. <i>Current Neuropharmacology</i> , 2017 , 15, 1107-1116	7.6	6
32	Quantitative Structure-Epigenetic Activity Relationships. <i>Challenges and Advances in Computational Chemistry and Physics</i> , 2017 , 303-338	0.7	4
31	Efficient and biologically relevant consensus strategy for Parkinsonß disease gene prioritization. <i>BMC Medical Genomics</i> , 2016 , 9, 12	3.7	15
30	Ligand-Based Virtual Screening Using Tailored Ensembles: A Prioritization Tool for Dual A2AAdenosine Receptor Antagonists / Monoamine Oxidase B Inhibitors. <i>Current Pharmaceutical Design</i> , 2016 , 22, 3082-96	3.3	10
29	Probing the Hypothesis of SAR Continuity Restoration by the Removal of Activity Cliffs Generators in QSAR. <i>Current Pharmaceutical Design</i> , 2016 , 22, 5043-5056	3.3	5
28	Harmonization of QSAR Best Practices and Molecular Docking Provides an Efficient Virtual Screening Tool for Discovering New G-Quadruplex Ligands. <i>Journal of Chemical Information and Modeling</i> , 2015 , 55, 2094-110	6.1	14
27	Toward the computer-aided discovery of FabH inhibitors. Do predictive QSAR models ensure high quality virtual screening performance?. <i>Molecular Diversity</i> , 2014 , 18, 637-54	3.1	5
26	Activity cliffs in drug discovery: Dr Jekyll or Mr Hyde?. <i>Drug Discovery Today</i> , 2014 , 19, 1069-80	8.8	103
25	Chemoinformatics profiling of ionic liquidsuncovering structure-cytotoxicity relationships with network-like similarity graphs. <i>Toxicological Sciences</i> , 2014 , 138, 191-204	4.4	9
24	Chemoinformatics profiling of ionic liquidsautomatic and chemically interpretable cytotoxicity profiling, virtual screening, and cytotoxicophore identification. <i>Toxicological Sciences</i> , 2013 , 136, 548-6	5 ^{4·4}	19
23	Desirability-based multi-criteria virtual screening of selective antimicrobial cyclic Ehairpin cationic peptidomimetics. <i>Current Pharmaceutical Design</i> , 2013 , 19, 2148-63	3.3	2

(2006-2013)

22	Recent advances on QSAR-based profiling of agonist and antagonist A3 adenosine receptor ligands. <i>Current Topics in Medicinal Chemistry</i> , 2013 , 13, 1048-68	3	4
21	Evolutionary computation and QSAR research. Current Computer-Aided Drug Design, 2013, 9, 206-25	1.4	22
20	Desirability-based multi-objective QSAR in drug discovery. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012 , 12, 920-35	3.2	11
19	Jointly handling potency and toxicity of antimicrobial peptidomimetics by simple rules from desirability theory and chemoinformatics. <i>Journal of Chemical Information and Modeling</i> , 2011 , 51, 3060-	. 97	21
18	Multidimensional drug design: simultaneous analysis of binding and relative efficacy profiles of N(6)-substituted-4Pthioadenosines A3 adenosine receptor agonists. <i>Chemical Biology and Drug Design</i> , 2010 , 75, 607-18	2.9	8
17	Prioritizing Hits with Appropriate Trade-Offs Between HIV-1 Reverse Transcriptase Inhibitory Efficacy and MT4 Blood Cells Toxicity Through Desirability-Based Multiobjective Optimization and Ranking. <i>Molecular Informatics</i> , 2010 , 29, 303-21	3.8	12
16	Global antifungal profile optimization of chlorophenyl derivatives against Botrytis cinerea and Colletotrichum gloeosporioides. <i>Journal of Agricultural and Food Chemistry</i> , 2009 , 57, 4838-43	5.7	7
15	Desirability-based methods of multiobjective optimization and ranking for global QSAR studies. Filtering safe and potent drug candidates from combinatorial libraries. <i>ACS Combinatorial Science</i> , 2008 , 10, 897-913		40
14	3D-MEDNEs: an alternative "in silico" technique for chemical research in toxicology. 2. quantitative proteome-toxicity relationships (QPTR) based on mass spectrum spiral entropy. <i>Chemical Research in Toxicology</i> , 2008 , 21, 619-32	4	35
13	Computational chemistry approach for the early detection of drug-induced idiosyncratic liver toxicity. <i>Journal of Computational Chemistry</i> , 2008 , 29, 533-49	3.5	42
12	Desirability-based multiobjective optimization for global QSAR studies: application to the design of novel NSAIDs with improved analgesic, antiinflammatory, and ulcerogenic profiles. <i>Journal of Computational Chemistry</i> , 2008 , 29, 2445-59	3.5	40
11	Stochastic molecular descriptors for polymers. 4. Study of complex mixtures with topological indices of mass spectra spiral and star networks: The blood proteome case. <i>Polymer</i> , 2008 , 49, 5575-558	3 .9	22
10	Quantitative Proteome-Property Relationships (QPPRs). Part 1: finding biomarkers of organic drugs with mean Markov connectivity indices of spiral networks of blood mass spectra. <i>Bioorganic and Medicinal Chemistry</i> , 2008 , 16, 9684-93	3.4	13
9	Multi-target QSPR assemble of a Complex Network for the distribution of chemicals to biphasic systems and biological tissues. <i>Chemometrics and Intelligent Laboratory Systems</i> , 2008 , 94, 160-165	3.8	6
8	Computational chemistry development of a unified free energy Markov model for the distribution of 1300 chemicals to 38 different environmental or biological systems. <i>Journal of Computational Chemistry</i> , 2007 , 28, 1909-23	3.5	67
7	Computational modeling tools for the design of potent antimalarial bisbenzamidines: overcoming the antimalarial potential of pentamidine. <i>Bioorganic and Medicinal Chemistry</i> , 2007 , 15, 5322-39	3.4	15
6	Chemometrics for QSAR with low sequence homology: Mycobacterial promoter sequences recognition with 2D-RNA entropies. <i>Chemometrics and Intelligent Laboratory Systems</i> , 2007 , 85, 20-26	3.8	23
5	Simple stochastic fingerprints towards mathematical modeling in biology and medicine 2. Unifying Markov model for drugs side effects. <i>Bulletin of Mathematical Biology</i> , 2006 , 68, 1527-54	2.1	9

4	Simple stochastic fingerprints towards mathematical modeling in biology and medicine. 3. Ocular irritability classification model. <i>Bulletin of Mathematical Biology</i> , 2006 , 68, 1555-72	2.1	9
3	Predicting multiple drugs side effects with a general drug-target interaction thermodynamic Markov model. <i>Bioorganic and Medicinal Chemistry</i> , 2005 , 13, 1119-29	3.4	41
2	QSAR for anti-RNA-virus activity, synthesis, and assay of anti-RSV carbonucleosides given a unified representation of spectral moments, quadratic, and topologic indices. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005 , 15, 1651-7	2.9	34
1	Unified drug-target interaction thermodynamic Markov model using stochastic entropies to predict multiple drugs side effects. <i>European Journal of Medicinal Chemistry</i> , 2005 , 40, 1030-41	6.8	23